[Oakbrook Terrace, June 15th, 2023] - Visible Genomics, a cutting-edge genomic data science company specializing in macular degeneration, is pleased to announce the appointment of Joe Boyd as its Business Development Director and Advisor. With a distinguished career spanning over 20 years in the diagnostic, pharmaceutical, and medical device industries, Boyd brings a wealth of expertise and a proven track record of success to his new role.

Currently serving as the President and Chief Operations Officer of Executive Biotech Advisors, Boyd advises start-ups, global multi-nationals, biotechs, specialty pharmaceutical firms, device and diagnostic firms, as well as venture capitalists, investors, and private equity firms.

Throughout his career, Boyd has demonstrated his ability to build customized sales, marketing, and commercial operations, supporting companies of all sizes. He strongly believes in fostering strong partnerships for company growth and success, actively engaging with key medical leaders and customers globally to build mutually beneficial relationships that ultimately benefit patients and communities.

Boyd's areas of therapeutic expertise encompass ophthalmology, oncology, urology, anti-infective, anti-inflammatory, allergy, asthma, dermatology, gastrointestinal, pulmonary endoscopy, and biliary endoscopy. He is a sought-after industry expert and frequently invited to speak at conferences and events, sharing his experiences and strategies on topics such as sales and marketing effectiveness, medical affairs, healthcare compliance, and ethical issues affecting diagnostic, pharmaceutical, and medical device companies.

Visible Genomics is confident that Boyd's vast experience and industry insights will significantly contribute to the company's continued growth and success. As a Business Development Director and Advisor, he will play a crucial role in guiding Visible Genomics' strategic decisions, commercial operations, and market expansion efforts.

About Visible Genomics:

Visible Genomics is a leading genomics data science company dedicated to eye health. With a focus on macular degeneration, the company is at the forefront of leveraging DNA and demographic data to identify the risk and progression of AMD. By leveraging cutting-edge technologies and scientific expertise, Visible Genomics aims to help prevent and slow the disease that impacts over 20 million people. For more information on macular degeneration tests or becoming a provider, please visit www.visiblegenomics.com.